

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Pentraxin 3/TSG-14 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse Pentraxin 3 is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human Pentraxin 3/TSG-14 Glu18-Ser381 Accession # P26022
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	1 µg/mL	See Below

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Pentraxin 3 (PTX3), TSG-14, was initially identified as a TNF- $\alpha$  or IL-1 $\beta$  inducible gene (1-3). It belongs to the pentraxin family, which was named originally for the homo-pentameric structure formed by its members (4). The pentraxin family is divided into two subfamilies: the "short" and the "long" pentraxins with approximate molecular weights of 25 kDa and 50 kDa, respectively. TSG-14 is a member of the long pentraxin subfamily, which also includes the *Xenopus laevis* XL-PXN1, the guinea pig apexin/p50, the rat neuronal pentraxin I (NPI) and NPR, the human neuronal pentraxin II (NPTX2) and the human neuronal activity-related pentraxin (5).

Mature secreted TSG-14 contains a pentaxin-like domain at its carboxy-terminus that shares 23-28% amino acid (aa) sequence similarity to C-reactive protein (CRP) and serum amyloid P component (SAP), which belongs to the short pentraxin subfamily. However, the N-terminal sequence of TSG-14 does not share aa sequence homology with any of the "short" pentaxins (3). Unlike CRP and SAP, which forms pentamers only, TSG-14 forms both pentameric and higher ordered oligomers (5). Similarly to CRP and SAP, TSG-14 binds to the complement cascade component C1q (6). However, TSG-14 does not bind to phosphoethanolamine, phosphocholine, or high pyruvate agarose, which are known ligands for CRP and SAP. TSG-14 is a marker of the acute phase response and is highly expressed in advanced atherosclerotic plaques (12). While CRP and SAP are primarily produced in the liver, TSG-14 expression is strongly up-regulated by TNF- $\alpha$ , IL-1 $\beta$ , and bacterial LPS in peripheral fibroblasts, endothelial cells, and macrophages (7). At the amino acid level, human and mouse TSG-14 share 88% aa sequence homology (8). TSG-14 concentration is elevated in the joint fluid of patients with rheumatoid arthritis (RA), indicating that TSG-14 may be a potential mediator of immune response (9). TSG-14 may also function in the regulation of the uptake and clearance of apoptotic cells by dendritic cells (10). In vivo study showed that TSG-14 transgenic mice are more resistant to sepsis and endotoxemia compared to wild type during the inflammatory injury (11). Increased expression of TSG-14 may enhance the immune response to protect the host from infection.

**References:**

1. Lee, T.H. *et al.* (1990) *Mol. Cell. Biol.* **10**:1982.
2. Breviario, F. *et al.* (1992) *J. Biol. Chem.* **267**:22190.
3. Lee, G.W. *et al.* (1993) *J. Immunol.* **150**:1804.
4. Osmand, A.P. *et al.* (1977) *Proc. Natl. Acad. Sci. USA* **74**:739.
5. Goodman A.R. *et al.* (1996) *Cytokine & Growth Factor Reviews* **7**:191.
6. Bottazzi, B. *et al.* (1997) *J. Biol. Chem.* **272**:32817.
7. Introna, M. *et al.* (1996) *Blood* **87**:1862.
8. Altmeyer, A. *et al.* (1995) *J. Biol. Chem.* **270**:25584.
9. Luchetti, M.M. *et al.* (2000) *Clin. Exp. Immunol.* **119**:196.
10. Rovere, P. *et al.* (2000) *Blood* **96**:4300.
11. Dias, A.A.M. *et al.* (2001) *J. Leukocyte Biol.* **69**:928.
12. Rolph, M.S. *et al.* (2002) *Arterioscler. Throm. Vasc. Biol.* **22**:e10-4.